Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -67.14 Million USD | -8.68% |
| 2022 | -61.78 Million USD | 47.57% |
| 2021 | -117.83 Million USD | 39.63% |
| 2020 | -195.18 Million USD | -39.3% |
| 2019 | -140.11 Million USD | -22.65% |
| 2018 | -114.23 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -15.78 Million USD | -1.74% |
| 2024 Q1 | -15.51 Million USD | -16.28% |
| 2023 Q2 | -14.93 Million USD | 3.92% |
| 2023 FY | -67.14 Million USD | -8.68% |
| 2023 Q3 | -23.32 Million USD | -56.16% |
| 2023 Q1 | -15.54 Million USD | -12.83% |
| 2023 Q4 | -13.34 Million USD | 42.78% |
| 2022 Q3 | -13.88 Million USD | 2.27% |
| 2022 Q2 | -14.21 Million USD | 28.62% |
| 2022 Q1 | -19.9 Million USD | 1.25% |
| 2022 FY | -61.78 Million USD | 47.57% |
| 2022 Q4 | -13.77 Million USD | 0.8% |
| 2021 FY | -117.83 Million USD | 39.63% |
| 2021 Q3 | -30.56 Million USD | 14.28% |
| 2021 Q4 | -20.15 Million USD | 34.04% |
| 2021 Q2 | -35.65 Million USD | 22.91% |
| 2021 Q1 | -46.24 Million USD | 9.97% |
| 2020 Q2 | -46.72 Million USD | 11.05% |
| 2020 Q1 | -52.52 Million USD | -7.26% |
| 2020 FY | -195.18 Million USD | -39.3% |
| 2020 Q4 | -51.37 Million USD | -15.26% |
| 2020 Q3 | -44.57 Million USD | 4.6% |
| 2019 Q4 | -48.97 Million USD | 10.7% |
| 2019 Q2 | -14.29 Million USD | 35.03% |
| 2019 Q1 | -22 Million USD | 67.18% |
| 2019 FY | -140.11 Million USD | -22.65% |
| 2019 Q3 | -54.84 Million USD | -283.56% |
| 2018 Q4 | -67.05 Million USD | 0.0% |
| 2018 FY | -114.23 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -13529.111% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -605.432% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -123.862% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -323.802% |
| Better Therapeutics, Inc. | -38.26 Million USD | -75.482% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -59.583% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -460.927% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -98.39% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -95.075% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 38.098% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -3233.313% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -97.468% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -43.007% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -4810.318% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -236.737% |
| Molecular Templates, Inc. | -10.46 Million USD | -541.534% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -377.856% |
| NexImmune, Inc. | -29.19 Million USD | -130.001% |
| Orgenesis Inc. | -53.63 Million USD | -25.183% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -30.898% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -85962.012% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -315.868% |
| Scopus BioPharma Inc. | -11.71 Million USD | -473.143% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 86.686% |
| Statera Biopharma, Inc. | -98.34 Million USD | 31.726% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -873.369% |
| Trevena, Inc. | -35.28 Million USD | -90.271% |
| Vaxxinity, Inc. | -58.28 Million USD | -15.198% |
| Vaccinex, Inc. | -22.88 Million USD | -193.393% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -6313.029% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -32.45% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -824.451% |